FDA grants traditional approval to pirtobrutinib for BTK-inhibitor-pretreated CLL/SLL
Evidence stage: Later-Stage HumanRegulatory status: FDA Approved
In the randomized, phase 3 BRUIN-CLL-321 trial, pirtobrutinib -- the first and only non-covalent (reversible) BTK inhibitor -- significantly extended progression-free survival compared with standard chemoimmunotherapy options in patients with…
Primary source cited
Last reviewed